P21 Accuracy of Overall Survival (OS) Extrapolations in French Cost-Effectiveness Reports Relative to Updated Data From Randomized Controlled Trials of Immune Checkpoint Inhibitors (ICIS)

A Gueye,A Juban,S Branchoux,Af Gaudin,F Colrat

doi:10.1016/j.jval.2022.09.033

P21 Accuracy of Overall Survival (OS) Extrapolations in French Cost-Effectiveness Reports Relative to Updated Data From Randomized Controlled Trials of Immune Checkpoint Inhibitors (ICIS)

A Gueye, A Juban + Show 3 more

Open Access

https://doi.org/10.1016/j.jval.2022.09.033

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Dec 1, 2022
License type: publisher-specific-oa

Affiliation: Université Paris Dauphine-PSL, Université Paris Cité, Bristol-Myers Squibb (France)

#Trials Of Immune Checkpoint Inhibitors #Accuracy Of Overall Survival + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

OS extrapolations of ICIs are required to inform cost-effectiveness analyses. This is often challenging given the short follow-up of randomized controlled trials (RCTs) available for model fitting. The objective of the study was to assess the accuracy of estimates of long-term OS predicted in French cost-effectiveness assessment reports (CEARs) using longer-term RCTs data.

Full Text